ReDNet Conference.
First International Conference on Novel Psychoactive Substances (NPS):
"The Ever-Changing World of Psychoactive Drugs"
will be held on 12-13 March 2012
in Budapest, Hungary.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Presentation by Gerald Humphris (Medical School, University of St Andrews, UK) on the occasion of the EESC hearing on New Psychoactive Substances (Brussels, 27 November 2013)
Dr. Roger Saltman - The NIAA Effort: Learning from the June RoundtableJohn Blue
The NIAA Effort: Learning from the June Roundtable - Dr. Roger Saltman, Group Director, Cattle and Equine Technical Services, Zoetis, from the 2016 NIAA Antibiotic Symposium - Working Together For Better Solutions, November 1 - 3, 2016, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2016-niaa-symposium-antibiotic-use-working-together-for-better-solutions
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Presentation by Gerald Humphris (Medical School, University of St Andrews, UK) on the occasion of the EESC hearing on New Psychoactive Substances (Brussels, 27 November 2013)
Dr. Roger Saltman - The NIAA Effort: Learning from the June RoundtableJohn Blue
The NIAA Effort: Learning from the June Roundtable - Dr. Roger Saltman, Group Director, Cattle and Equine Technical Services, Zoetis, from the 2016 NIAA Antibiotic Symposium - Working Together For Better Solutions, November 1 - 3, 2016, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2016-niaa-symposium-antibiotic-use-working-together-for-better-solutions
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
The explosion in the number of applications (apps) designed for the medical and wellness sectors has been noted by many. Recently we have seen increased presence of truly medical apps, in addition to consumer health and wellbeing apps, designed for clinical professionals and patients with medical conditions.
Consumer based mHealth apps typically allow people to do old things in new ways, such as recording health measures digitally rather than on paper. We see this also with medical apps, where increases in the quality and efficiency of existing health care models provide clinical staff with digital tools that replace paper based documentation. In rare and exciting cases we are also seeing mHealth applications that are doing things in entirely new ways to drive real innovation in health care delivery through mobile devices.
The aim of the tutorial is to highlight real world, high impact mobile research that is relevant to the key discipline of Mobile HCI. Thus, the tutorial will be application rather than academically focused. The tutorial will highlight the wide range of mHealth applications available that go far beyond trackers and behavior change tools and encourage researchers to look beyond consumer applications in their research. Four key areas of mHealth applications will be covered including Apps for the HealthyWell, mHealth in Hospitals, Practice and Clinical Apps and Patient Apps and will cover applications for health assessment, treatment and triage, behavior change, chronic illness, mental health, adolescent health, rehabilitation and age care with a focus on the need for rigorous evaluation and efficacy analysis.
Quality of Management and Treatment Services for Sick Children at Patent and ...JSI
Patent and Proprietary Medicine Vendors (PPMVs) are an important source of treatment for sick children in Nigeria. Concerns are widespread that PPMVs provide poor quality services, although evidence is limited. The Maternal and Child Survival Program (MCSP), in close coordination with public and private state and national-level stakeholders, is working to improve and assess the quality of integrated community case management (iCCM) services for childhood malaria, diarrhea and pneumonia that PPMVs provide. This approach, entitled “Enhancing Quality iCCM through PPMVs and Partnerships (EQuiPP),” supports 542 PPMVs registered with the Pharmaceutical Council of Nigeria (PCN) to provide quality services in four local government areas (LGAs) in Ebonyi and Kogi states.
Their results suggest that PPMVs are a significant source of care for childhood illness, but that the quality of services were less than adequate at baseline. The introduction of the EQuiPP approach improved quality of services. The EQuiPP approach does not provide external inputs such as per diems or transport costs, and therefore is a promising , sustainable approach to improve availability of medications and quality of services at PPMV shops. Rigorous quality assessments at PPMV shops can demonstrate improvements and gaps.
This poster was presented by Kate Gilroy at the Fifth Global Symposium on Health System Research in Liverpool in October.
Dr. Paul Sundberg - Emerging Disease Response Planning Updates, Working on Ou...John Blue
Emerging Disease Response Planning Updates, Working on Our Preparedness - Dr. Paul Sundberg, Vice President, Science and Technology, National Pork Board, from the 2015 Minnesota Pork Congress, January 21-22, Minneapolis, MN, USA.
More presentations at http://www.swinecast.com/2015-minnesota-pork-congress
Keeping It Real:Resources for Implementing Evidence-based Public Health Progr...MargaretFarrell
Through this workshop, participants will
not only become familiar with how to use the tools they need to identity and address health outcomes, but
understand the benefits of virtual communities of practice as a means to engage researchers and practitioners around implementing cancer control programs.
will introduce participants to the Cancer Control P.L.A.N.E.T portal and the Research to Reality Community of Practice. (#NCIR2R)
Presentation given at the NATIONAL HEALTH OUTREACH CONFERENCE (#NHOC) Promoting Connections to Create Healthy Individuals, Families and Communities May 8, 2015
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
The explosion in the number of applications (apps) designed for the medical and wellness sectors has been noted by many. Recently we have seen increased presence of truly medical apps, in addition to consumer health and wellbeing apps, designed for clinical professionals and patients with medical conditions.
Consumer based mHealth apps typically allow people to do old things in new ways, such as recording health measures digitally rather than on paper. We see this also with medical apps, where increases in the quality and efficiency of existing health care models provide clinical staff with digital tools that replace paper based documentation. In rare and exciting cases we are also seeing mHealth applications that are doing things in entirely new ways to drive real innovation in health care delivery through mobile devices.
The aim of the tutorial is to highlight real world, high impact mobile research that is relevant to the key discipline of Mobile HCI. Thus, the tutorial will be application rather than academically focused. The tutorial will highlight the wide range of mHealth applications available that go far beyond trackers and behavior change tools and encourage researchers to look beyond consumer applications in their research. Four key areas of mHealth applications will be covered including Apps for the HealthyWell, mHealth in Hospitals, Practice and Clinical Apps and Patient Apps and will cover applications for health assessment, treatment and triage, behavior change, chronic illness, mental health, adolescent health, rehabilitation and age care with a focus on the need for rigorous evaluation and efficacy analysis.
Quality of Management and Treatment Services for Sick Children at Patent and ...JSI
Patent and Proprietary Medicine Vendors (PPMVs) are an important source of treatment for sick children in Nigeria. Concerns are widespread that PPMVs provide poor quality services, although evidence is limited. The Maternal and Child Survival Program (MCSP), in close coordination with public and private state and national-level stakeholders, is working to improve and assess the quality of integrated community case management (iCCM) services for childhood malaria, diarrhea and pneumonia that PPMVs provide. This approach, entitled “Enhancing Quality iCCM through PPMVs and Partnerships (EQuiPP),” supports 542 PPMVs registered with the Pharmaceutical Council of Nigeria (PCN) to provide quality services in four local government areas (LGAs) in Ebonyi and Kogi states.
Their results suggest that PPMVs are a significant source of care for childhood illness, but that the quality of services were less than adequate at baseline. The introduction of the EQuiPP approach improved quality of services. The EQuiPP approach does not provide external inputs such as per diems or transport costs, and therefore is a promising , sustainable approach to improve availability of medications and quality of services at PPMV shops. Rigorous quality assessments at PPMV shops can demonstrate improvements and gaps.
This poster was presented by Kate Gilroy at the Fifth Global Symposium on Health System Research in Liverpool in October.
Dr. Paul Sundberg - Emerging Disease Response Planning Updates, Working on Ou...John Blue
Emerging Disease Response Planning Updates, Working on Our Preparedness - Dr. Paul Sundberg, Vice President, Science and Technology, National Pork Board, from the 2015 Minnesota Pork Congress, January 21-22, Minneapolis, MN, USA.
More presentations at http://www.swinecast.com/2015-minnesota-pork-congress
Keeping It Real:Resources for Implementing Evidence-based Public Health Progr...MargaretFarrell
Through this workshop, participants will
not only become familiar with how to use the tools they need to identity and address health outcomes, but
understand the benefits of virtual communities of practice as a means to engage researchers and practitioners around implementing cancer control programs.
will introduce participants to the Cancer Control P.L.A.N.E.T portal and the Research to Reality Community of Practice. (#NCIR2R)
Presentation given at the NATIONAL HEALTH OUTREACH CONFERENCE (#NHOC) Promoting Connections to Create Healthy Individuals, Families and Communities May 8, 2015
Similar to Risk reduction on new drugs, a spanish experience (iván fornís) (20)
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Risk reduction on new drugs, a spanish experience (iván fornís)
1. Risk Reduction on New Drugs,
•
Risk Reduction on New Drugs, a Spanish experience
a Spanish Experience
Iván Fornís Espinosa
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 1
2. •
1. The evolution of the use of new synthetic drugs in
Risk Reduction on New Drugs, a Spanish experience
Spain. Information collected by Energy Control through its
Drug Checking service and the online counseling service
adressed to drug users.
2. Our proposal to provide objective information to the
users of these drugs in order to conduct low-risk
consumptions.
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 2
3. What is ?
1. Risk reduction project in Spain.
•
2. Peer to peer actions.
Risk Reduction on New Drugs, a Spanish experience
3. Responsible drug use.
4. Resources:
Development and dissemination of information
Drug Checking service aimed at drug users.
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 3
4. In recent years we have observed in
our project three phenomena:
•
Risk Reduction on New Drugs, a Spanish experience
1. An increment in the number of
samples of new drugs provided by
the users.
2. An increment of types of new
drugs, also called research
chemicals or legal highs.
3. An increment in the number of
requests for information about
new drugs.
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 4
6. Increment of types of new drugs
•
Risk Reduction on New Drugs, a Spanish experience
80
70 68
60
50
40 39
32
30
20 19
10
5 4
0
2006 2007 2008 2009 2010 2011
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 6
7. Increment in the number of requests for information
about new drugs.
•
Risk Reduction on New Drugs, a Spanish experience
50
47
45
40
35
30
25
22
21
20
15
10
5
2
0
2008 2009 2010 2011
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 7
8. Peculiarities of our country on New Drugs
1. In Spain there hasn´t been a
•
big expansion of the use of new
Risk Reduction on New Drugs, a Spanish experience
drugs.
2. Little presence of the smart-
shop phenomenon (or head-
shop). The most important
distribution channel has been
on the Internet and grow-shops.
3. Adaptation of the comercial
product names to spanish topics
such as
Mazazo, Fuego, Cocopollo, etc.
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 8
9. Peculiarities of our country on New Drugs
4. we began to observe the presence of new drugs as
•
adulterants of illicit drugs
Risk Reduction on New Drugs, a Spanish experience
Sold as composition Samples
Ecstasy pill 2C-B 53
Ecstasy pill 2C-I 4
Ecstasy (crystal) Methylone 12
Ecstasy (pill, crystal) Mephedrone 11
Cocaína Mephedrone 2
Methamphetamine Mephedrone 2
Ketamine Mephedrone 4
Ketamine Methoxetamine 6
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 9
10. Our approach
1. Development and dissemination of update and objective
•
information about risk reduction on new drugs:
Risk Reduction on New Drugs, a Spanish experience
Scientific articles
Trip reports and personal communication
Give information in recreational places
Give information in our drug checking services
Give information through web, forums and social networks
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 10
11. Our approach
2. Direct communication to general drug users about the
•
emergence of new drugs as adulterants of other drugs to
Risk Reduction on New Drugs, a Spanish experience
inform them (ex. PMMA in legal highs).
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 11
12. Our approach
3. Notice the proper agencies of the findings, especially
•
the
Risk Reduction on New Drugs, a Spanish experience
- EMCDDA
- Ministry of Health
- regional councils
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 12
13. Our approach
4. Updating the analysis
•
service to expand its capacity
Risk Reduction on New Drugs, a Spanish experience
to detect new substances in
timeframes as short as
possible.
5. Training project staff to have
updated knowledge as possible
of the phenomenon.
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 13
14. Conclusions (1)
Energy Control has only had access to samples provided
voluntarily by consumers; this has allowed us to observe
•
particularly the phenomenon of adulteration of other drugs
Risk Reduction on New Drugs, a Spanish experience
with these new compounds.
Studies of new drugs, which keep track of the products
sold in stores or online head-shops, have failed to detect
this phenomenon.
This could add risk to consumers because these people do
not take precautions to consume.
Thus, having information of samples submitted by users
becomes a source of invaluable information
complementary to information obtained by other means
(for example, direct purchases or police seizures).
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 14
15. Conclusions (2)
In this sense, having services such as drug checking
•
Risk Reduction on New Drugs, a Spanish experience
service, a web-site for drug users or be present in
recreational contexts allows us direct contact with
consumers and work specifically with these aspects as the
information on these new drugs and taking care strategies
and the associated demystify certain beliefs such as
greater security in front of these illegal drugs.
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 15
16. Conclusions (3)
The phenomenon of new drugs is extremely dynamic and
•
Risk Reduction on New Drugs, a Spanish experience
is able to rapidly introduce new substances on the market.
This causes, at times, when we are able to prepare and
distribute updated information about these new
drugs, these leaving the market and appear new ones.
This is produced by the application of prohibitive legislation
on new drugs as the only way to address the problem.
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 16
17. Thank you
•
PMMA (paramethoxymethamphetamine) in “legal Highs” in Spain.
Iván Fornís Espinosa
(Energy Control – ABD)
analisis@energycontrol.org
info@enrgycontrol.org
•
•
Energy Control-ABD. Iván Fornís Espinosa.
analisis@energycontrol.org | info@energycontrol.org | www.energycontrol.org | www.abd-ong.org • 17